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University, School of Medicine, New Haven, CT. 
 
The optimal timing of expander-implant exchange in the setting of post 
mastectomy radiation remains unclear with prior reports yielding inconsistent and 
variable results. The purpose of this study was to characterize complications 
associated with the sequencing of expander-implant breast reconstruction before 
or after radiation therapy and to compare the outcomes between early (< 4 
months) and late (>4 months) expander-implant exchange in the subset of 
patients who received radiation prior to exchange. 
The medical records of all patients receiving post-mastectomy radiation 
therapy in the setting of tissue expander-implant breast reconstruction between 
June 2004 – June 2011 at Yale-New Haven hospital were reviewed 
retrospectively. Patients were first classified as having undergone expander-
implant exchange prior to the initiation of radiation or after the completion of 
radiation.  Patients who underwent expander-implant exchange after radiation 
were then classified as having undergone exchange early (<4 months following 
radiation) or late (>4 months following radiation). All complications requiring 
additional surgery or hospitalization were recorded.  
Fifty-five eligible patients were identified as having undergone 56 two-
stage tissue expander-implant breast reconstructions. 22 reconstructions 
underwent exchange prior to radiation and 34 reconstructions underwent 
exchange following radiation. There was no significant difference in overall 
complication rate (54.55% vs 47.06%, p=0.785) or reconstruction failure rate 
(13.64% vs 20.59%, p=0.724) between the two cohorts.  20 reconstructions 
underwent exchange <4 months following radiation and14 underwent exchange 
>4 months following radiation. There was no significant difference in overall 
complication rate (40% vs 57.14%, p=0.487) or failure rate (25% vs 14.29%, 
p=0.672) between the two groups. Trends suggest a higher rate of infection in 
patients who underwent earlier exchange (30% vs 14.29%, p=0.422) and a 
higher rate of capsular contracture in patients who underwent later exchange 
(5% vs 21.43%, p=0.283), however statistical significance was not reached. 
Our findings suggest that neither the sequencing nor timing of expander-
implant exchange in the setting of radiation has an impact on overall complication 
or reconstruction failure rate. However, the timing of exchange may impact the 
type of complication encountered.  
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I. INTRODUCTION  
 
 
Breast cancer remains the most commonly diagnosed cancer in women. Recent 
statistics indicate that 1 in every 8 American women will develop breast cancer at 
some point over the course of her lifetime(1). Over the past decade, there has 
been a marked rise in the number of women seeking breast reconstruction as 
part of their breast cancer treatment, with over 96,000 breast reconstruction 
operations performed in the United States in 2011 alone (2).  During this same 
time period, the prevalence of adjuvant oncologic therapies, including chemo-and 
radiation therapies has increased as well. Ultimately, the management of breast 
cancer today requires a multidisciplinary approach, and it has become imperative 
to gain a better understanding of the impact of breast reconstruction on adjuvant 
treatments, and the impact that these treatments have on reconstruction 
outcomes. 
 
Following the diagnosis of breast cancer, a patient may be referred to a medical 
oncologist for hormonal or chemotherapy, a breast surgeon for a lumpectomy or 
mastectomy, a radiation oncologist for radiation therapy, and a reconstructive 
surgeon to explore their reconstructive options. Care must be taken to 
appropriately coordinate all of these elements in order to optimize both oncologic 
treatment and reconstructive results. Figure 1 depicts a possible timeline of 







FIGURE 1. Breast Cancer Management Timeline 
Several variables must be coordinated in the management of breast cancer 
patients. Neoadjuvant chemotherapy may be administered prior to mastectomy in 
order to shrink the primary tumor size. Reconstruction may be performed 
immediately at the time of mastectomy or in a delayed fashion, following the 




Post-mastectomy radiation therapy is becoming an increasingly common part of 
breast cancer treatment today; it has been shown to decrease the risk of 
locoregional recurrence and is associated with prolonged survival times (3).  
Current absolute indications for radiation therapy include: presence of four or 
more positive lymph nodes, tumor size greater than 5cm, and positive margins 
following mastectomy (3-6).  Factors associated with a higher risk of recurrence 
include: age at diagnosis < 40, histological grade 3 tumor, presence of 
lymphovascular invasion, <6 nodes removed during axillary dissection, significant 
nodal extracapsular spread, and presence of 1-3 positive nodes(7).  Individuals 
with these characteristics are now being offered radiation at an increasing rate. 
 
As a result, there has been a marked rise in the number of patients presenting for 


















breast cancer treatment.  Implant-based breast reconstruction in the setting of 
post-mastectomy radiation therapy remains a challenge.  Radiation therapy 
engenders changes in mastectomy flap perfusion, which may result in infection, 
tissue necrosis, capsular contracture, implant extrusion, wound dehiscence, and 
complete reconstructive failures (8-11).  The deleterious effect of radiation tends 
to be more pronounced with prosthetic reconstruction as compared to autologous 
reconstruction(12-14). However, autologous reconstruction is not always a viable 
option for patients.  Autologous reconstruction necessitates an additional donor 
site and often requires a longer post-operative hospitalization and recovery 
period.  Subsequently, implant based breast reconstruction remains the most 
popular option for immediate breast reconstruction today(15). 
 
The majority of prosthetic reconstructions are performed as two stage tissue 
expander-implant reconstructions. Typically, the tissue expander is placed under 
the pectoralis major muscle, within the breast pocket at the time of mastectomy.  
Immediate placement of the tissue expander helps to preserve the integrity of the 
breast skin envelope and maintain the patient’s natural inframammary fold. 
Periodic expansions of the tissue expanders occur over the course of weeks to 
months. Once the breast has reached an adequate volume and the soft tissue 
pocket has been appropriately expanded, the tissue expander is removed and 











FIGURE 2. Tissue Expander-Implant Breast Reconstruction 
Typically the tissue expander is placed at the time of mastectomy. Following 
period expansions, the tissue expander is replaced with a permanent implant. 
 
The necessity of radiation therapy complicates the typical breast reconstruction 
timeline.  Given the high risk of complications associated with radiation, many 
surgeons advocate delaying reconstruction until all adjuvant therapies have been 
completed (12, 16). In Kronowitz’s 2007 review of immediate versus delayed 
reconstruction, he reports that if radiation is required, delayed reconstruction is 
usually the best course, however, if radiation is not required, immediate 
reconstruction should be performed (16).  The benefits of immediate breast 
reconstruction are well documented in the plastic surgery literature. Patients who 
undergo immediate reconstruction have been shown to have improved 
psychosocial well-being and superior final aesthetics when compared to those 
who undergo delayed reconstructions (17, 18). 
 
Unfortunately, the requirement of radiation therapy in patients who are clinically 










reports may not be available until days later. In patients undergoing tissue 
expander-implant reconstruction, by the time the necessity of radiation has been 
determined, the tissue expander has already been placed.   
 
At this point, the plastic surgeon and radiation oncologist are faced with the 
question of how to optimally coordinate the timing of the rest of the reconstruction 
with radiation treatment.  Is it better to complete the two-stage reconstruction and 
perform the exchange to permanent implant prior to radiation, thus irradiating the 
permanent implant, or to perform the exchange following completion of radiation, 
thus irradiating the tissue expander? 
 
Although complications of implant based breast reconstruction in the setting of 
radiation are well described, little is known about the physiological and temporal 
effects of how radiation therapy influences the sequence of two-stage expander-
implant reconstruction. Prior studies that have attempted to answer this question 
have yielded inconclusive and inconsistent results with some reporting exchange 
prior to radiation results in fewer complications(19), while others report no 
difference(20-22).   
 
Additionally, from an oncologic perspective, we know there is a therapeutic 
benefit to administering radiation soon after mastectomy. A 2003 review 
examining the impact of delayed initiation of radiation found that the 5-year local 
recurrence rate was significantly higher in patients whose radiation was started 
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more than 8 weeks after surgery(23).  Does performing expander-implant 
exchange prior to radiation contribute towards a delay in initiation of radiation 
therapy? To date, no previous study has investigated this question.    
 
Lastly, for patients who undergo exchange following the completion of radiation, 
there is limited data that describes the optimal time to wait following completion 
of radiation before proceeding with exchange to permanent implants.  Most 
surgeons recommend waiting between 3 – 6 months following the completion of 
radiation before proceeding with exchange to permanent implant. However, 
these time frames are largely subjective and not evidence based.
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Statement of Purpose 
 
Purpose 
The purpose of this study was to investigate and characterize the impact of 
timing of expander-implant exchange and post-mastectomy radiation therapy on 
breast reconstruction outcomes. 
 
Specific Aims 
The specific aims of this study were: 
1. to characterize the complications associated with the sequencing of 
expander-implant exchange before or after post-mastectomy 
radiation therapy1, 
2. to determine the impact of sequencing of expander-implant 
exchange on delivery of radiation therapy, and  
3. to compare the outcomes between early (< 4 months) and late (>4 
months) expander-implant exchange in the subset of patients who 
received post-mastectomy radiation therapy prior to expander-
implant exchange. 
 
                                                 
1 To clarify, if the expander-implant exchange occurs prior to radiation, then the 
permanent implant is getting irradiated. If the expander-implant exchange occurs 
after radiation, then the tissue expander is getting radiated. Another way to 
interpret the first aim of our study is: to characterize the complications associated 




The null hypotheses were: 
1. sequencing of expander-implant exchange before or after post-
mastectomy radiation does not have an impact on complications, 
2. sequencing of expander-implant exchange does not impact the 
delivery of radiation therapy, and 
3. there is no difference between the outcomes of patients who 
undergo early or late expander-implant exchange. 
 
As alternative hypotheses, the investigators posited that: 
1. the sequencing of expander-implant exchange would impact the 
complications seen in reconstruction patients, 
2. the sequencing of expander-implant exchange would impact the 
timing to radiation therapy administration, and 
3. there would be a difference in outcomes in patients who undergo 




Under the auspices of the Yale University School of Medicine’s Human 
Investigation Committee, we identified all patients who underwent tissue 
expander-implant breast reconstruction at Yale New Haven Hospital and 
received post-mastectomy radiation therapy as part of their breast cancer 
treatment between June 2004 – June 2011. 
 
A de-identified database was then created and maintained by the thesis author 
for the purposes of this study. An extensive retrospective review of patient 
medical records was performed in order to screen for possible study inclusion 
and collect demographic, therapeutic, and operative data for subsequent 
analysis. 
 
In total, seventy-three patients were identified as having undergone immediate 
tissue expander placement at the time of mastectomy followed by radiation 
therapy at Yale New Haven Hospital.  Thirteen of those patients were excluded 
because they chose to undergo autologous reconstruction instead of exchanging 
their expanders for permanent implants following radiation therapy. An additional 
five patients were excluded because their tissue expanders were permanently 
removed prior to implant exchange, thus they did not complete the two-stage 
expander-implant reconstruction.  For patients who underwent bilateral breast 
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reconstruction and received post-mastectomy radiation to both breasts, each 
breast was recorded as an independent data point. 
 
After exclusions, a total of fifty-five eligible patients were identified with fifty-six 
breasts that underwent completed tissue expander-implant reconstruction and 
received post-mastectomy radiation therapy.  
 
Sequencing of Expander-Implant Exchange and Radiation 
 
In order to address the first aim of this study, the impact of the sequencing of 
expander-implant exchange on reconstructive outcomes, we divided our sample 
into two cohorts: breasts that underwent expander-implant exchange prior to the 
initiation of radiation therapy and breasts that underwent expander-implant 
exchange after the completion of radiation therapy (figure 3).  The primary 
outcomes of interest were complications requiring additional, unplanned 









FIGURE 3. Sequencing of Expander-Implant Exchange and Radiation 
The sample of eligible breasts was divided into two cohorts: those that underwent 















and those that underwent expander-implant exchange after radiation (irradiating 
the tissue expander). 
 
 
Impact of Sequencing on Delivery of Radiation Therapy 
 
For the second aim of this study, the impact of sequencing of expander-implant 
exchange on delivery of radiation therapy, we excluded all patients who received 
neoadjuvant chemotherapy, as its administration may impact the timing of post-
mastectomy adjuvant therapies. In the remaining patients, the number of days 
from mastectomy/tissue expander placement to the initiation of radiation therapy 
was recorded for comparison. The primary outcome of interest for this aim was 
the number of days to initiation of radiation. 
 
Timing of Expander-Exchange Following Radiation 
 
For the third aim of this study, comparing the outcomes between early and late 
expander-implant exchange following radiation completion, we only included 
breasts that underwent expander-implant exchange after the completion of 
radiation therapy. Breasts were then classified as having undergone exchange 
early, less than 4 months after radiation, or late, more than 4 months after 
radiation (figure 4). The time point of 4 months was chosen because it provided 
groups of relatively equal size and characteristics for comparison. The primary 
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outcomes of interest for this aim were complications requiring additional, 







FIGURE 4. Timing of Expander-Implant Exchange After Radiation  
The sample of eligible breasts that underwent expander-implant exchange after 
radiation (irradiated tissue expanders) was divided into two cohorts: those that 
underwent early exchange to permanent implant (within 4 months of completion 
of radiation therapy) and those that underwent late exchange to permanent 
implant (greater than 4 months after completion of radiation therapy) 
 
 
All complications requiring additional surgery or hospitalization were recorded. 
Complications included: cellulitis/prosthesis infection, wound dehiscence/implant 
extrusion, seroma, hematoma, capsular contracture and suspected implant leak.  
For the purposes of this study, we defined reconstruction failure as removal of 
the permanent implant following initial successful expander-implant exchange. 
Length of follow up was defined as the interval between date of 
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Independent t-tests were performed to determine whether any significant 
differences existed between the groups being compared. Additional statistical 
analysis was performed using multivariate regression analysis, student’s t test 
and Fischer exact test where appropriate.  Statistical significance was 
determined where p < 0.05. Analysis was performed using IBM SPSS Statistics 
v20.0 software. 
 
Contributions to Methods 
The thesis author performed all aspects of this project including: thorough review 
of the literature, preparation and submission of HIC documents, data collection, 
database maintenance, and statistical analysis. In addition, I prepared an 
abstract with data from this project that was accepted for an oral presentation at 
the Northeastern Society of Plastic Surgeons in Boston, Massachusetts in 
September 2012. I also prepared a manuscript of this study that has been 
accepted for publication in an upcoming issue of Annals of Plastic Surgery. 
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III. RESULTS 
Sequencing of Expander-Implant Exchange and Radiation 
From June 2004 – June 2011, a total of 56 two-stage tissue expander-implant 
breast reconstruction surgeries were performed (by six different surgeons) that 
also underwent radiation as part of their breast cancer treatment.  Of these, 22 
completed exchange for permanent implant prior to initiation of radiation 
(irradiated their permanent implants) and 34 underwent exchange to permanent 
implant following completion of radiation (irradiated their tissue expanders). 
Patient characteristics can be found in Table A.  
 




(n = 22) 
Exchange After 
Radiation 
(n = 34) 
p 
 
Age, mean (y) 48.1 44.8 0.25 
BMI, mean (kg/m2) 24.3 25.4 0.53 
Race (n, %)   0.28 
     White      16 (72.7) 30 (88.2)  
     Black 4 (18.2) 2 (5.9)  
     Hispanic 2 (9.1) 1 (2.9)  
     Other  1 (2.9)  
Smoking Status (n, %)   0.13 
     None 11 (50.0) 21 (61.8)  
     Former 6 (27.3) 12 (35.3)   
     Current 4 (18.2) 1 (2.9)  
Comorbidities (n, %) 
     Diabetes 1 (4.6) 1 (2.9) 0.75 
     Hypertension 3 (13.6) 4 (11.8) 0.84 
Follow Up Time, mean(mos) 46.0 27.3 0.00* 
     * Denotes statistical significance 
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There was no statistical difference between two groups’ demographic data; the 
cohorts were similar with respect to age at mastectomy, BMI, race, smoking 
status, and comorbidities. The group that completed exchange following radiation 
had a significantly shorter follow up time.  




(n = 22) 
Exchange After 
Radiation 
(n = 34) 
p 
 
Histology (n, %)   0.29 
     Infiltrating Ductal (IDC) 13 (59.1) 26 (76.5)  
     Infiltrating Lobular (ILC) 4 (18.2) 3 (8.8)  
     IDC with lobular features 2 (9.1) 4 (11.8)  
     IDC with tubular features 1 (4.6) 0 (0.0)  
     Mucinous carcinoma 0 (0.0) 1 (2.9)  
     Adenosquamous 1 (4.6) 0 (0.0)  
Pathologic Stage (n, %)   0.41 
     0 0 (0.0) 3 (8.8)  
     1 1 (4.6) 1 (2.9)   
     2A 6 (27.3) 9 (26.5)  
     2B 11 (50.0) 11 (32.4)  
     3A 4 (18.2) 7 (20.6)  
     3B 0 (0.0) 3 (8.8)  
Neoadjuvant Chemotherapy 
(n, %) 8 (36.4) 17 (50) 0.32 
Adjuvant Chemotherapy (n, %) 17 (77.3) 25 (73.5) 0.75 
Chest Wall XRT (n, %) 22 (100.0) 34 (100.0) 1 
Supraclavicular XRT (n, %) 19 (86.3) 29 (85.3) 0.80 
Axilla XRT (n, %) 1 (4.6) 7 (20.6) 0.10 
Internal Mammary XRT (n, %) 0 (0.0) 3 (8.8) 0.15 
Scar Boost XRT (n, %) 0 (0.0) 1 (2.9) 0.42 
Mastectomy (n, %)   0.09 
     Simple 11 (50.0) 10 (29.4)  
     Modified Radical 10 (45.5) 24 (70.6)  
     Unknown 1 (4.6) 0 (0.0)  
Skin Sparing (n, %) 3 (13.6) 5 (14.7) 0.91 
Nipple Sparing (n, %) 1 (4.6) 8 (23.5) 0.06 
Implant Type – silicone (n, %) 9 (40.9) 28 (82.4) 0.00* 
ADM (n, %) 9 (40.9) 27 (79.4) 0.01* 
     * Denotes statistical significance 
        ADM = acellular dermal matrix 
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Oncologic and treatment characteristics of the two groups can be found above, in 
Table B.  The groups were similar in their oncologic characteristics including 
tumor histology and cancer staging.  Additionally, the two groups were similar in 
the adjuvant therapies received.  Of note, the group that completed exchange 
following radiation had significantly higher use of both acellular dermal matrix 
(ADM)2 and silicone implants during the reconstruction process. 
 
The overall complication and reconstructive failure rates can be found in figure 3. 
There was no significant difference between the two groups with respect to 
overall complication rate (54.5% vs 47.1%, p = 0.58). The group that underwent 
exchange after radiation experienced a higher reconstructive failure rate of 
20.6% versus the 13.6% rate of reconstructive failure in the group that underwent 
exchange before radiation; however, this difference was not statistically 
significant.  
                                                 
2
 Acellular dermal matrix (ADM) is a soft tissue lattice that is becoming more prevalent 
in prosthetic based breast reconstruction. It is frequently employed as a sling or coverage 
reinforcement, providing the tissue expander or implant with additional support within 
the breast envelope. 
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FIGURE 3: Overall Complication and Failure Rates 
There was no statistically significant difference between the two groups with 
respect to overall complication or reconstructive failure rate. 
 
The complications requiring additional, unplanned surgery or hospitalization that 
occurred in both groups included: infection, wound dehiscence/implant extrusion, 
seroma, hematoma, capsular contracture, and suspected implant leak. The 
specific break down of complications in each group can be found in Table C. 
While there was no statistically significant difference between the two groups with 
respect to infection, wound dehiscence, seroma or hematoma, the group that 
underwent exchange prior to radiation, thus irradiating their permanent implant, 
experienced a significantly higher incidence of capsular contracture (40.9% vs 





























(n = 22) 
Exchange After 
Radiation 
(n = 34) 
p 
 
 n % n %  
Infection 4 18.2 8 23.5 0.75 
Wound Dehiscence/Extrusion 1 4.5 5 14.7 0.39 
Seroma 0 0 1 2.9 1 
Hematoma 0 0 2 5.9 0.51 
Capsular Contracture 9 40.9 4 11.8 0.02* 
Suspected Implant Leak 1 4.5 0 0 0.39 
     * Denotes statistical significance 
The group that underwent exchange before radiation (irradiating the permanent 
implant) experienced significantly more operative capsular contracture 
complications (40.9% vs 11.8%, p = 0.02) than the group that underwent 
exchange after radiation (irradiating the tissue expander). 
 
The results of a multivariate logistic regression analysis to explore predictors of 
experiencing complications can be seen in Table D. Of note, the sequencing of 
exchange with relation to radiation did not increase the odds of developing a 
complication (OR = 0.998, p = 0.998). The only variable associated with an 
overall increased risk of experiencing a complication was current smoking activity 
(OR = 14.866, p = 0.046). 
 
TABLE D. Predictors of Complication Among All Patients 
Variables Odds Ratio 95% CI P 
Age 1.009 0.95-1.07 0.774 
BMI 1.053 0.95-1.17 0.338 
Current Smoker 14.866 1.04-211.64 0.046* 
Silicone Implant 4.670 0.88-24.70 0.070 
Neoadjuvant Chemotherapy 0.194 0.05-0.74 0.016* 
Sequence of Expander-Implant Exchange 0.998 0.21-4.83 0.998 




Impact of Sequencing on Initiation of Radiation Administration 
In order to address our second aim, the impact of sequencing of expander-
implant exchange on delivery of radiation, we excluded all patients from our 
sample that received neoadjuvant chemotherapy.  This left 14 patients who 
underwent exchange prior to radiation and 17 patients who underwent exchange 
following radiation.  Both groups underwent adjuvant chemotherapy following 
mastectomy/tissue expander placement and prior to the initiation of radiation 
therapy.  In the group that experienced exchange after radiation, the initiation of 
radiation therapy occurred an average of 188.0 days following mastectomy, while 
the group that underwent exchange prior to radiation therapy experienced an 
average of 220.4 days from mastectomy to initiation of radiation therapy, 
representing a statistically significant difference. (Table E).  
 




(n = 14) 
Exchange After 
Radiation  
(n = 17) 
p 
 
Time to Radiation start, 
mean (days) 220.4 188.0 0.034* 
     *Denotes statistical significance 
 
Timing of Expander-Implant Exchange Following Radiation 
To address the impact of timing of exchange following radiation, we only 
examined the patients who underwent exchange to permanent implant following 
radiation completion. Of those 34 patients, 20 underwent exchange to permanent 
implant within 4 months (early) of completing radiation therapy and 14 underwent 
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exchange to permanent implant greater than 4 months (late) following the 
completion of radiation therapy. The average time between radiation completion 
and exchange to permanent implant was 2.75 ± 0.76 months for the early group 
and 7.25 ± 2.81months for the late group. Table F compares the patient and 
treatment characteristics. The groups were similar in demographics, 
comorbidities, and treatment characteristics. 
 





(n = 20) 
Late 
Exchange 
(n = 14) 
p 
 
Age, mean (y) 47.1 41.6 0.13 
BMI, mean (kg/m2) 26.0 24.5 0.55 
Race (n, %)   0.68 
     White      17 (85.0) 13 (92.9)  
     Black 1 (5.0) 1 (7.1)  
     Hispanic 1 (5.0) 0 (0)  
     Other 1 (5.0) 0 (0)  
Smoking Status (n, %)   0.31 
     None 14 (70.0) 7 (50.0)  
     Former 6 (30.0) 6 (42.9)   
     Current 0 (0) 1 (7.1)  
Comorbidities (n, %) 
     Diabetes 1 (5.0) 0 (0) 1 
     Hypertension 3 (15.0) 1 (7.1) 0.63 
Follow Up Time, mean(mos) 26.5 28.5 0.68 
Time from PMRT to exchange, mean(mos) 2.83 7.35 0.00* 
Neoadjuvant Chemotherapy (n, %) 10 (50.0) 7 (50.0) 1 
Adjuvant Chemotherapy (n, %) 13 (65.0) 12 (85.7) 0.25 
Implant Type – Silicone (n, %) 18 (90.0) 10 (71.4) 0.20 
Alloderm (n, %) 16 (80.0) 11 (78.6) 1 




In comparing the complications between early and late exchange, the group that 
underwent early exchange had a 40% overall complication rate, whereas the 
group that underwent late exchange had a 57.1% complication rate. This did not 
represent a statistically significant difference. When looked at overall 
reconstructive failure rate, the group that underwent early exchange had a 25% 
failure rate while the group that underwent exchange late had a 14.3% failure 




FIGURE 4: Comparison of Overall Complication and Failure Rates Between 
Early and Late Expander-Implant Exchange 
There was no statistically significant difference in overall complication (40% vs 
























TABLE G: Complications Necessitating Surgery/Hospitalization Across 
Early and Late Expander-Implant Exchange Groups 
 
Early Exchange 
(n = 20) 
Late Exchange 
(n = 14) p 
 n % n %  
Infection 6 30.0 2 14.3 0.42 
Wound Dehiscence/Extrusion 3 15.0 2 14.3 1 
Seroma 1 5.0 0 0 1 
Hematoma 0 0 2 14.3 0.16 
Capsular Contracture 1 5.0 3 21.4 0.28 
     *Denotes statistical significance 
 
Analysis of specific complications using Fischer’s exact test can be seen in Table 
G. When looking at the specific complications, there was no statistically 
significant difference between the groups with respect to rate of infection, wound 
dehiscence/extrusion, seroma, hematoma, or capsular contracture. Further 
exploring the data trends, it is interesting to note that the group that underwent 
exchange early experienced an infection rate of 30%, more than double the 
14.3% infection rate seen in the group that underwent exchange late. Whereas, 
the group that underwent exchange late had a 21.4% rate of capsular 
contracture, four times the 5.0% rate of capsular contracture seen in the group 
that underwent exchange early.  Given the small numbers of the sample, neither 





As the indications for adjuvant post-mastectomy therapy increase, we can 
anticipate seeing an increase in the number of patients presenting for breast 
reconstruction who will also undergo radiotherapy as part of their treatment. 
While many have championed the use of autologous reconstruction to minimize 
the high complication and reconstructive failure rates associated with irradiating 
implants, implant-based reconstructions remain the most common form of 
immediate breast reconstruction.  Despite the increasing prevalence of this issue, 
there remains a lack of consensus regarding the optimal timing and coordination 
of radiation into the prosthetic reconstructive timeline.  The purpose of this study 
was to evaluate the relationship between expander-implant exchange and timing 
of radiation administration, and how this relationship ultimately impacts 
reconstruction complications in the context of two-stage tissue expander-implant 
breast reconstruction.  
 
Sequencing of Expander-Implant Exchange and Radiation 
 
Our study represents one of the largest reported series investigating the impact 
of sequencing of expander-implant exchange with relation to radiation therapy.  
This report demonstrates that there is no statistically significant difference in 
overall complication or reconstructive failure rates if the exchange to permanent 
implant is performed before or after radiation, thus we were unable to reject our 
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initial null hypothesis. However, we did find that sequencing may impact the type 
of complication experienced, as our results indicated that patients who 
underwent exchange prior to radiation, thus irradiating their permanent implants. 
experienced a higher incidence of capsular contracture necessitating additional 
operative interventions.  
 
The higher incidence of capsular contracture could possibly be explained by the 
fact that during most expander-implant exchange operations, a capsulotomy or 
capsulectomy is performed. A capsulotomy is a procedure in which the capsule 
(scar tissue that surrounds the tissue expander or implant) is surgically released. 
In a capsulectomy, the entire capsule is surgically removed.  All patients who 
undergo prosthetic reconstruction develop some form of a capsule; it is the result 
of the body’s normal physiologic immune response when presented with a 
foreign body. The capsule itself can be beneficial in supporting the expander or 
implant, helping to preserve breast shape and maintain breast projection.  
However, capsular contracture is a pathologic process that occurs when excess 
scar tissue develops, resulting in a physically painful, firm, and aesthetically 
displeasing breast. Radiation significantly increases the risk of developing 
capsular contracture.  For patients that underwent exchange to permanent 
implant after radiation, any pathologic capsular formation that occurred 
surrounding the tissue expander could have been addressed at the time of the 
exchange to permanent implant, circumventing the need for an additional, 
unplanned operation.  In the patients who underwent exchange prior to radiation, 
 25 
thus irradiating their permanent implant, the only way to address any radiation-
induced capsule formation was through an additional, unplanned capsulotomy or 
capsulectomy procedure. 
 
Previous single center studies that have attempted to investigate the impact of 
sequencing of expander-implant exchange related to radiation have yielded 
variable and inconsistent results.  The majority of these studies have been 
retrospective in nature and limited by a small number of patients. Furthermore, 
most single center studies have been limited by their own institutional protocols 
regarding sequencing, resulting in the publication of outcomes related to 
irradiating tissue expanders or outcomes related to irradiating permanent 
implants, with very few studies directly comparing the two. 
 
Ascherman et al. explored the outcomes of patients who underwent two-stage 
expander-implant breast reconstruction, comparing groups that underwent 
neoadjuvant radiotherapy prior to mastectomy and groups that underwent 
radiotherapy during the tissue expander stage to patients who did not receive 
any radiotherapy at all.  There was no analysis of patients who underwent 
radiation therapy to a permanent implant. Their finding of a 40.7% overall 
complication rate included both neoadjuvant radiation and adjuvant radiation 
groups.  Based on this, they concluded that there is an overall increase in 
complications associated with radiation and prosthetic breast reconstruction. 
However, their analysis did not provide additional information regarding the 
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optimal timing of radiotherapy(11).  Lin et al. found comparable 43.8% and 41.2% 
complication rates in patients who underwent neoadjuvant radiotherapy and 
adjuvant radiotherapy prior to exchange, respectively(24).  
 
Cordeiro and McCarthy’s analysis of tissue expander-implant outcomes included 
29 patients who received neoadjuvant radiotherapy and 62 patients who were 
irradiated after expander-implant exchange.  Their findings included a statistically 
significant increase in capsular contracture in patients who were irradiated after 
exchange as compared to patients who received neoadjuvant radiation (50.1% 
vs 20%)(25). Our findings of increased incidence of capsular contracture in 
patients who undergo exchange prior to radiation are consistent with this prior 
report.  
 
Nava et al. conducted the largest retrospective study investigating the 
sequencing of exchange, consisting of 109 patients who underwent exchange 
prior to radiation therapy and 50 patients who underwent exchange following 
radiation therapy. Their results showed a statistically significant difference in 
complication and failure rate between the two groups with a 6.4% failure rate for 
exchange prior to radiation and 40% failure rate for exchange following radiation, 
contrary to our results which suggested that there is no difference in overall 
complication or failure rate with respect to radiotherapy sequencing(19).  Of note, 
our study only included patients who had completed both stages of tissue 
expander-implant reconstruction, whereas the Nava study included patients who 
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had their reconstructions fail during the tissue expander stage and patients who 
opted for autologous reconstruction instead of an implant following tissue 
expansion.  If we had included the patients who experienced failure during the 
tissue expander stage and patients who chose to undergo autologous 
reconstruction following undergoing radiation to their tissue expanders, we also 
would have seen a much higher complication and failure rate in the group that 
underwent exchange to permanent implants after radiation completion.  
 
Of note, when we performed our multivariate regression analysis, examining the 
variables that could be predictors of increased complications, sequencing of the 
expander-exchange was not associated with worse outcomes. The only variable 
that was associated with worse outcomes was smoking. This finding is consistent 
with the literature. In Petersen et al.’s 2012 retrospective study of 208 prosthetic 
breast reconstruction patients found smoking to be the most significant risk factor 
for infection and post-operative complications(26).   
 
The limitations of this report include the retrospective nature of the study. With 
retrospective reviews of this nature, we are limited in the amount and variability 
of information provided in the medical record.  While our numbers reflect one of 
the largest series to investigate this question, there remained areas where 
statistical significance was not achieved.  Performing a power analysis based on 
our results indicated that in order to observe the 7% difference in failure rate with 
80% power, we would need an n of 390 patients in each group. No previous 
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single institution study that has explored this subject has reached this sample 
size, suggesting that a multi-institutional study may be the best way to answer 
this question in the future. 
 
Additionally, we only included patients who had completed two-stage expander-
implant reconstruction. By excluding both patients who experienced failure or 
permanent removal of their tissue expander without undergoing implant 
reconstruction and patients who opted to undergo flap reconstruction following 
tissue expander radiation, it is possible that we minimized the actual complication 
rate experienced in the irradiated tissue expander group. 
 
The mastectomies and breast reconstruction operations were performed by a 
number of different surgeons.  Reconstructive surgeon preference has a 
significant impact on the time course of when operations occur with two-stage 
expander-implant breast reconstructions. However, our total sample size was too 
small to control for the impact of surgeon bias.  
 
Impact of Sequencing on Initiation of Radiation Administration 
 
From an oncologic viewpoint, radiation oncologists would prefer to initiate 
radiation therapy as soon as possible following mastectomy. The results of our 
study indicated a statistically significant delay of 32 days in the initiation of post-
mastectomy radiation therapy administration when the exchange procedure 
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occurs prior to radiation start. The clinical significance of this delay is not 
currently known. Prior studies examining the impact of immediate breast 
reconstruction on oncologic outcomes have indicated acceptable disease 
control(27). This is the first study to examine the impact of sequencing of implant 
exchange on initiation of adjuvant radiation. 
 
Logically, it makes sense that there would be a delay when performing the 
exchange prior to radiation administration. Typically, radiation oncologists will not 
proceed with radiation administration until a patient is well healed post-
operatively. Furthermore, if there are any signs of infection or wound 
complications following the operation, this could further delay the start of 
radiation administration as it would add additional days or even weeks until the 
skin is satisfactorily healed enough to begin radiation therapy.  
 
Timing of Expander-Implant Exchange Following Radiation 
 
The duration of time to wait following radiation completion before proceeding with 
expander-implant exchange remains a question of clinical judgment for most 
surgeons.  For patients who will not receive radiation, the literature is supportive 
of proceeding with exchange to permanent implants as early as 1 month 
following the completion of expansion (28, 29).  Understandably, the addition of 
radiation complicates this timeline, and current recommendations range from 
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waiting anywhere from 3-6 months following radiation completion before 
proceeding with additional reconstructive operations (28, 30, 31). 
  
While our results suggest that there is no difference in overall complication or 
failure rates between groups who underwent exchange <4 months and >4 
months following radiation therapy, there does appear to be a trend in the types 
of complications, with respect to the time of exchange.  Patients who underwent 
exchange earlier had a higher incidence of cellulitis, whereas patients who 
underwent exchange later had a higher incidence of capsular contracture.   
 
The pathophysiology of radiotherapy’s effects on skin and soft tissue may explain 
these differences in complication type. The acute changes related to radiation 
occur within the first 70 days following radiation administration. They include 
erythema, skin reactions, and moist desquamation. All of which may leave the 
skin more susceptible to infection and possible cellulitis. The later effects of 
radiation are related to dermal injury and include tissue atrophy, subcutaneous 
fibrosis and necrosis, which may contribute toward the higher rates of capsular 
contracture seen in patients who underwent exchange later.(32)   
 
Most recently, in 2012, Peled et al., were the first to explore this question of 
timing of exchange following radiation in the literature, comparing the failure rates 
of 88 patients who underwent expander-implant exchange less than 6 months 
after completion of post-mastectomy radiation therapy to 39 patients who 
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underwent exchange at least 6 months following post-mastectomy radiation 
therapy. Contrary to our findings, their results indicated a statistically significant 
increase in failure of 22.4% vs 7.7%, p = 0.036, in the group undergoing 
exchange earlier. Additionally, when they further subdivided the time interval of 
exchange following radiation, they found the highest rate of failure, 28.6%, in the 
group that underwent exchange less than 3 months following radiation 
completion as compared to the 17.9% failure rate in the group that underwent 
exchange between 3 to 6 months following radiation completion.(31)  Our 
findings also indicated a higher failure rate in the group that underwent 
reconstruction earlier (25% vs 14.29%), however these results did not reflect a 
significant difference. It is possible that as our numbers increase, this difference 
may become more pronounced, and we would be able to draw similar 
conclusions. Additionally, implant exchange occurred sooner following radiation 
completion at our institution with a mean time between radiation and exchange to 
permanent implant of 2.75 months and 7.25 months in our study, while their 
study had a mean time between radiation completion and exchange of 3.4 
months and 8.6 months.   
 
The small sample size of our study limited the power of our generated results, 
and we were unable to reach significance when we were comparing specific 
complications between groups.  In order to obtain a better understanding 
regarding the impact of timing of exchange following radiation completion on 
outcomes, it would be necessary to perform a larger study with an greater 
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number of patients in each group. Performing a power calculation based on 
these results indicated that in order to see the 12% difference in failure rate with 
80% power, we would need an n of 176 patients in each group.  Again, this 
would be another question that may be better served by performing a multi-
institutional study, where we’re able to analyze outcomes from a greater pool.  
 
As mentioned previously, the fact that our study contained the results of six 
surgeons, as opposed to solely examining the outcomes of a single surgeon 
introduced some degree of surgeon bias into this study. The decision on when to 
proceed with expander-implant exchange following radiation is largely at the 
surgeon’s discretion, and many have well developed preferences of which they 




Our findings suggest that neither the sequencing nor the timing of expander-
implant exchange in the setting of post-mastectomy radiation therapy has an 
impact on overall complication or reconstruction failure rate. The timing of 
exchange, however, may have an influence on the types of complications 
experienced by patients.  Performing implant exchange prior to radiation, and 
thus radiating a permanent implant, results in a higher incidence of capsular 
contracture, necessitating additional surgical revisions.  
 
The sequencing of expander-implant exchange does impact the start time of 
radiation therapy administration. Performing the exchange prior to radiation can 
result in a delay of initiation of adjuvant therapy. 
 
 Additionally, while there was no difference in overall complication or 
reconstructive failure rates with respect to timing of exchange following 
completion of radiation, there may be an association with different types of 
complications depending on the timing of exchange.  Performing exchange to 
permanent implant earlier following the completion of radiation therapy may 
result in increased risk of infectious related complications, whereas performing 
exchange later following the completion of radiation therapy may result in an 
increased risk of fibrotic related complications. 
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Ultimately, the management of breast cancer today requires the collaboration of 
a team of doctors from varying specialties in order to optimize both oncologic 
outcomes and reconstructive results. All patients who are presenting with newly 
diagnosed breast cancer should be provided with information regarding the 
various treatment modalities and all available reconstruction options. Patients 
should also be made aware of the impact that adjuvant therapies can have on 
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